{"id":"NCT00194012","sponsor":"University Hospitals Cleveland Medical Center","briefTitle":"Study of Aripiprazole (Abilify) Versus Placebo in Children With Subsyndromal Bipolar Disorder","officialTitle":"Aripiprazole in At-Risk Children With Symptoms of Bipolar Disorder","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2004-08","primaryCompletion":"2012-05","completion":"2012-06","firstPosted":"2005-09-19","resultsPosted":"2014-05-05","lastUpdate":"2017-06-26"},"enrollment":62,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Bipolar Disorder"],"interventions":[{"type":"DRUG","name":"Aripiprazole","otherNames":["Abilify"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Aripiprazole-Randomized Phase","type":"ACTIVE_COMPARATOR"},{"label":"Placebo-Randomized Phase","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to test the effectiveness and tolerability/safety of aripiprazole (Abilify) in children with subsyndromal symptoms of bipolar disorder who also have a parent with bipolar disorder and other family member with a mood disorder.","primaryOutcome":{"measure":"Young Mania Rating Scale (YMRS)","timeFrame":"Baseline","effectByArm":[{"arm":"Abilify Randomized Phase","deltaMin":24.8,"sd":6.8},{"arm":"Placebo Randomized Phase","deltaMin":21.6,"sd":6.1}],"pValues":[]},"eligibility":{"minAge":"5 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":6,"exclusionCount":17},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":31},"commonTop":["Headache","Stomach ache","Increased appetite","Sedation","Emesis"]}}